FDA will survey how visuals distract viewers

Share this article:
The FDA will test broadcast-style ads for a bogus blood pressure drug as part of a survey aimed at determining how visuals may distract viewers from risk information. The survey of 2,400 consumers—ages 40 and up—will feature several executions of the bogus ads to evaluate recall and comprehension of risk information. 
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.